AI English summary of an SEC filing — figures as filed
Zoetis ZTSZoetis said total revenue rose $190 million, or 10%, over the 3 months ended March 31, 2024 compared with the prior-year period, and rose $239 million, or 12%, on an operational basis, which excludes the impact of foreign exchange.
Key points
AI summaryZoetis said total revenue rose $190 million, or 10%, over the 3 months ended March 31, 2024 compared with the prior-year period, and rose $239 million, or 12%, on an operational basis, which excludes the impact of foreign exchange.
The company said U.S. segment revenue rose $158 million, or 16%, and International segment revenue rose $29 million, or 3%. It said International operational revenue rose $79 million, or 8%, and explained that foreign exchange reduced revenue by $50 million, or 5%.
The company said its cost of sales as a percentage of revenue remained flat at 29.4% compared with the prior-year period. It also said SG&A expenses rose $42 million, or 8%, and R&D expenses rose $20 million, or 14%.
Zoetis said net cash used in investing activities was $131 million and net cash used in financing activities was $524 million for the 3 months ended March 31, 2024. It also said it repurchased 1.8 million shares for $339 million in the same period, and that the remaining approved repurchase authorization as of March 31, 2024 was $1.2 billion.
Key figures
Quarter ended March 31, 2024
- Revenue
- $2.2B
- Net income
- $599M
- EPS
- $1.31
- Operating cash flow
- $595M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Total revenue rose $190 million (10%) in Q1 2024
Zoetis said total revenue rose $190 million, or 10%, over the 3 months ended March 31, 2024 compared with the prior-year period, and rose $239 million, or 12%, on an operational basis, which excludes the impact of foreign exchange.
Source · Based on the MD&A text of the filing
U.S. Revenue Up 16%, International Revenue Up 3%
The company said U.S. segment revenue rose $158 million, or 16%, and International segment revenue rose $29 million, or 3%. It said International operational revenue rose $79 million, or 8%, and explained that foreign exchange reduced revenue by $50 million, or 5%.
Source · Based on the MD&A text of the filing
Cost of Sales Ratio Flat at 29.4%; SG&A and R&D Up
The company said its cost of sales as a percentage of revenue remained flat at 29.4% compared with the prior-year period. It also said SG&A expenses rose $42 million, or 8%, and R&D expenses rose $20 million, or 14%.
Source · Based on the MD&A text of the filing
Investing and Financing Cash Outflows; Share Buybacks
Zoetis said net cash used in investing activities was $131 million and net cash used in financing activities was $524 million for the 3 months ended March 31, 2024. It also said it repurchased 1.8 million shares for $339 million in the same period, and that the remaining approved repurchase authorization as of March 31, 2024 was $1.2 billion.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…